Silo Pharma Inc
Silo Pharma Inc (SILO) is a small‑cap, clinical‑stage biopharmaceutical company developing novel therapeutics, with public attention on psychedelic‑inspired compounds and other central nervous system treatments. With a market capitalisation of roughly $7.66 million, the company is likely pre‑revenue and dependent on research milestones, trial results and financing activity rather than steady sales. That profile can lead to high share‑price volatility and a significant risk of dilution if new funding is required. Positive clinical news or regulatory progress can materially re‑rate the stock, while setbacks may cause sharp declines. Liquidity is often limited in companies this size, making buying or selling larger positions difficult. This summary is educational only and not personalised advice; such stocks are typically suitable only for investors who accept high risk, long time horizons and the possibility of losing most or all capital. Consider diversification and consulting a regulated financial adviser for individual suitability.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Silo Pharma's stock due to its significant potential growth.
Financial Health
Silo Pharma is generating modest revenue and cash flow, but its profitability remains uncertain.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SILO
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Trial milestones ahead
Clinical data and regulatory steps can materially affect valuation, though outcomes are uncertain and may require further funding.
Scientific focus
Interest in psychedelic‑inspired and CNS therapies could attract attention, but scientific and regulatory hurdles remain significant.
Speculative profile
Very small market cap and likely low liquidity mean high volatility and potential dilution — suitable only for risk‑tolerant investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
